

## EQA round: CSFK2/23 - Cerebrospinal Fluid Diagnostics

Deadline: 27.11.2023

Setup: groups - R (manufacturer of kit); minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D <sub>max</sub> = acceptable difference
SD = standard deviation	CVP = consensus of all participants	LL = lower limit
CV = coefficient of variation	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	UL = upper limit
N <sub>tot</sub> = total number of the results		N <sub>eva</sub> = number of the results assessed
N <sub>out</sub> = number of the results removed before calculation		N <sub>suc</sub> = number of successful results
		S <sub>rel</sub> = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	Comparability					N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub> [%]	
							AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL				
<b>(398) Albumin</b>	[mg/L]				46							46	46	100	
<b>Sample K</b>		228	19	8,4	46		CVP	228	6,9	23%	175	281	46	46	100
(60) Roche		222	11	4,8	16	0							16		
(149) Siemens (Dade, BN, Dimension)		240	14	5,9	8	0							8		
(162) Siemens (Atellica)		217	43	20	7	0							7		
(179) Siemens		228	17	7,5	6	0							6		
Other					9	0							9		
								1x 1, 3x 12, 2x 58, 3x 91							
<b>(396) Glucose</b>	[mmol/L]				45							45	45	100	
<b>Sample K</b>		4	0,093	2,3	45		CVP	4	0,034	18%	3,28	4,72	45	45	100
(58) Beckman Coulter (AU)		4,02	0,089	2,2	6	0							6		
(60) Roche		3,98	0,075	1,9	21	0							21		
(162) Siemens (Atellica)		4,02	0,074	1,8	6	0							6		
Other					12	0							12		
								1x 0, 2x 1, 4x 46, 1x 49, 1x 75, 2x 179, 1x 188							
<b>(401) IgA</b>	[mg/L]				20							20	20	100	
<b>Sample K</b>		4,39	0,34	7,7	20		CVP	4,39	0,19	32%	2,98	5,8	20	20	100
(149) Siemens (Dade, BN, Dimension)		4,31	0,31	7,2	8	0							8		
Other					12	0							12		
								3x 12, 4x 91, 2x 162, 3x 179							
<b>(399) IgG</b>	[mg/L]				35							35	32	91	
<b>Sample K</b>		18,2	2	11	35		CVP	18,2	0,84	24%	13,8	22,6	35	32	91
(60) Roche		16,1	2,1	13	12	0							12		
(149) Siemens (Dade, BN, Dimension)		19	1,2	6,2	8	0							8		
Other					15	0							15		
								4x 12, 4x 91, 3x 162, 4x 179							
<b>(402) IgM</b>	[mg/L]				23							23	23	100	
<b>Sample K</b>		2,65	0,21	7,8	23		CVP	2,65	0,11	31%	1,82	3,48	23	23	100
(91) Binding Site		2,76	0,089	3,2	5	0							5		
(149) Siemens (Dade, BN, Dimension)		2,65	0,19	7,3	8	0							8		
Other					10	0							10		
								3x 12, 2x 60, 2x 162, 3x 179							
<b>(411) Intrathec. synt. IgA</b>	[mg/L]				20							20	20	100	
<b>Sample K</b>												20	20	100	
(0) not specified		0	0		20	0	CVP	0	asym.	0	1	20			
<b>(410) Intrathec. synt. IgG</b>	[mg/L]				35							35	34	97	
<b>Sample K</b>												35	34	97	
(0) not specified		0	0		35	1	CVP	0	asym.	0	1	35			
<b>(412) Intrathec. synt. IgM</b>	[mg/L]				23							23	23	100	
<b>Sample K</b>												23	23	100	
(0) not specified		0	0		23	0	CVP	0	asym.	0	1	23			
<b>(403) Lactate</b>	[mmol/L]				46							46	46	100	
<b>Sample K</b>		1,53	0,081	5,3	46		CVP	1,53	0,029	20%	1,22	1,84	46	46	100
(58) Beckman Coulter (AU)		1,52	0,067	4,4	5	0							5		
(60) Roche		1,57	0,058	3,7	24	0							24		
(162) Siemens (Atellica)		1,45	0,11	7,7	6	0							6		
Other					11	0							11		
								3x 1, 2x 49, 1x 75, 2x 179, 2x 188, 1x 998							
<b>(413) Barrier permeability</b>	[·10 <sup>-3</sup> ]				45							45	45	100	
<b>Sample K</b>												45	45	100	
(0) not specified		5,07	0,43	8,5	45	0	CVP	5,07	0,16	25%	3,8	6,34	45		